复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

休市中 08-14 16:08:36

67.300

-0.750

-1.10%

最高69.000	最低66.850	成交量27.90万
今开67.550	昨收68.050	日振幅3.16%
总市值366.79亿	流通市值234.20亿	总股本5.45亿
成交额1,881万	换手率0.08%	流通股本3.48亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":67.3,"timestamp":1786694916006,"preClose":68.05,"halted":0,"volume":279006,"delay":0,"changeRate":-0.011021307861866276,"floatShares":348000000,"shares":545000000,"eps":1.7563976302114805,"marketStatus":"休市中","change":-0.75,"latestTime":"08-14 16:08:36","open":67.55,"high":69,"low":66.85,"amount":18809245,"amplitude":0.031594,"askPrice":67.3,"askSize":53600,"bidPrice":67.1,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":1.7568420763526507,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":68.05,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.5281005935877418,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2658966292","title":"港股异动 | 复宏汉霖(02696.HK)再涨超3% 抗PD-1单抗H药汉斯状亮相《新闻联播》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658966292","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658966292?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:04","pubTimestamp":1786417486,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000320264.USD","HK0000306701.USD","02696","HK0000320223.HKD","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657690168","title":"港股异动 | 复宏汉霖(02696)再涨超8% 8项研究成果将亮相WCLC 汉斯状进入NHS医保体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2657690168","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657690168?lang=zh_cn&edition=full","pubTime":"2026-08-07 15:08","pubTimestamp":1786086504,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖再涨超8%，本周累计涨幅超20%。复宏汉霖将在本次大会上公布其创新产品的多项最新研究成果，涵盖PD-L1ADCHLX43在胸腺鳞癌领域的I期研究数据，以及抗PD-1单抗H药汉斯状在广泛期小细胞肺癌、局限期小细胞肺癌和肺大细胞神经内分泌癌领域的7项研究数据。值得注意的是，近日，复宏汉霖自主研发的抗PD-1单抗汉斯状获英国国家卫生与临床优化研究所推荐、有望进入英国国家医疗服务体系惠及广泛期小细胞肺癌患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","HK0000306685.HKD","HK0000165453.HKD","KCAI","HK0000320264.USD","HK0000306701.USD","02696","BK1161","BK4585","VXUS","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106551895","title":"复宏汉霖2026年7月股份变动月报表：H股增发23,500股","url":"https://stock-news.laohu8.com/highlight/detail?id=1106551895","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106551895?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:01","pubTimestamp":1785834061,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司于2026年8月4日发布截至2026年7月31日的股份变动月报表。报告显示，公司法定/注册股本总额为人民币545,230,103元，其中截至本月底，H股普通股从上月底的347,786,147股增至347,809,647股，增发23,500股；非上市股份则维持197,420,456股不变。本期主要变化来自2025年7月21日采纳的2025H股购股权计划。截至本月末，共有11,692,250份购股权处于存续状态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107194796","title":"复宏汉霖（02696）将于2026年8月21日审议中期业绩及分红事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1107194796","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107194796?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:23","pubTimestamp":1785748981,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司（02696）8月3日公告称，公司董事会已订于2026年8月21日（星期五）召开会议。董事会将审议并通过公司及其附属公司截至2026年6月30日止六个月的中期业绩报告，并讨论派发中期股息（如有）等相关事宜。\n公告并披露，复宏汉霖董事会成员包括：主席及非执行董事张文杰；执行董事朱俊；非执行董事陈启宇、陈玉卿、关晓晖、刘毅、王星立；独立非执行董事苏德扬、陈力元、宋瑞霖及张一昊。\n公司称，将在董事会会议后按监管要求及时公布中期业绩及相关决议。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656254433","title":"港股异动 | 复宏汉霖(02696.HK)午后涨超7% HLX43胸腺鳞癌数据与H药肺癌等研究成果即将亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2656254433","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656254433?lang=zh_cn&edition=full","pubTime":"2026-08-03 14:55","pubTimestamp":1785740142,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000306701.USD","HK0000165453.HKD","HK0000320264.USD","HK0000320223.HKD","02696","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163574391","title":"复宏汉霖获NMPA批准：HLX43联合贝伐珠单抗临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1163574391","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163574391?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:34","pubTimestamp":1785486845,"startTime":"0","endTime":"0","summary":"复宏汉霖（02696.HK）宣布，中国国家药品监督管理局（NMPA）已正式批准其HLX43联合贝伐珠单抗的临床试验申请。这一里程碑式进展，标志着该公司在肿瘤免疫联合疗法领域的布局迈出了关键一步。此次获批的临床试验，旨在评估HLX43与抗血管生成药物贝伐珠单抗联用的安全性及疗效。该联合方案有望通过协同作用，为特定类型的癌症患者带来新的治疗选择。复宏汉霖表示，将迅速启动相关临床试验，并严格遵循监管要求推进研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000320264.USD","HK0000165453.HKD","HK0000306685.HKD","02696","HK0000320223.HKD","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655490356","title":"复宏汉霖(02696)：注射用HLX43(靶向PD-L1抗体偶联药物)联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗的临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655490356","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655490356?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:33","pubTimestamp":1785486809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，注射用HLX43联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗的临床试验申请获国家药品监督管理局批准。HLX43是由本公司利用许可引进的新型DNA拓扑异构酶I抑制剂小分子毒素-肽链连接子与本公司自主研发的靶向PD-L1的抗体进行偶联开发的靶向PD-L1的抗体偶联药物，拟用于晚期/转移性实体瘤的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696","HK0000306701.USD","IBBJ","IBBQ","HK0000165453.HKD","HK0000306685.HKD","PSYK","MDTX","BK4023","HK0000320223.HKD","LU1169589451.USD","LU1169590202.USD","BMED","PD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179713464","title":"复宏汉霖（02696）HLX3902在华完成首例给药，开展mCRPC及晚期实体瘤Ⅰ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1179713464","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179713464?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:30","pubTimestamp":1785403835,"startTime":"0","endTime":"0","summary":"2026年7月30日，复宏汉霖发布自愿公告称，公司自主研发的三特异性抗体注射液HLX3902用于转移性去势抵抗性前列腺癌及其他晚期实体瘤的Ⅰ期临床试验已在中国境内完成首例患者给药。公司计划在条件具备后于澳大利亚开展相关临床试验。本次Ⅰa期研究为开放性首次人体临床试验，旨在评估HLX3902在mCRPC及其他晚期实体瘤患者中的安全性、耐受性、药代动力学特征及初步疗效。公告由复宏汉霖董事会主席Wenjie Zhang签署，日期为2026年7月30日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655827679","title":"复宏汉霖(02696)：HLX3902注射液用于转移性去势抵抗性前列腺癌及其他晚期实体瘤治疗的1期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2655827679","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655827679?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:28","pubTimestamp":1785403685,"startTime":"0","endTime":"0","summary":"本研究的主要目的为评估HLX3902在转移性去势抵抗性前列腺癌及其他晚期实体瘤患者中的安全性和耐受性，确定其最大耐受剂量。临床前研究显示，HLX3902抗肿瘤疗效及安全性良好，有望获得临床获益。2026年5月及6月，HLX3902分别于澳大利亚及中国境内获许可开展用于转移性去势抵抗性前列腺癌及其他晚期实体瘤治疗的1期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：HLX3902注射液用于转移性去势抵抗性前列腺癌及其他晚期实体瘤治疗的1期临床研究于中国境内完成首例患者给药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["HK0000165453.HKD","HK0000306685.HKD","HK0000320264.USD","02696","HK0000306701.USD","BK1161","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145405224","title":"港股直击 | 生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145405224","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145405224?lang=zh_cn&edition=full","pubTime":"2026-07-22 10:11","pubTimestamp":1784686287,"startTime":"0","endTime":"0","summary":"7月22日，港股生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%，复宏汉霖、药明康德、君实生物涨超2%。消息面上，美国总统特朗普当地时间7月21日在社交媒体发文表示，自2026.8.1起，所有进口到美国的仿制药将在未来两年内继续适用零关税。两年期满后，相关产品将被征收100%的关税，期限为一年。此后，关税将进一步提高至200%。","market":"hk","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股直击 | 生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","02359","09926","09995","01877","02696","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652137289","title":"复宏汉霖(02696.HK)授出合共413万份购股权及23万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2652137289","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652137289?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:31","pubTimestamp":1784298691,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000306701.USD","HK0000320264.USD","HK0000306685.HKD","HK0000320223.HKD","HK0000165453.HKD","BK1161","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162074543","title":"复宏汉霖（02696.HK）授出413万份购股权及23万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=1162074543","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162074543?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:31","pubTimestamp":1784298675,"startTime":"0","endTime":"0","summary":"2026年7月17日，复宏汉霖董事会根据公司2025年H股购股权计划及2025年H股受限制股份单位计划，通过向合资格人士合计授出4,130,000份购股权及230,000份受限制股份单位的决议。– 其余230,000份购股权分四批按年度归属，80%与年度关键绩效指标挂钩，20%与市值目标挂钩，可在未达标情况下顺延一年，仍未达标则失效。在本次授予后，公司根据计划授权限额尚可授出23,748,088股H股；服务提供者分项限额下剩余7,222,422股H股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2651410636","title":"复宏汉霖：HLX18临床试验中国境内首例患者给药完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2651410636","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651410636?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:03","pubTimestamp":1784192580,"startTime":"0","endTime":"0","summary":"7月16日，复宏汉霖（02696）发布公告，近日，公司自主研发的纳武利尤单抗生物类似药HLX18在多种已切除实体瘤患者中开展的国际多中心1期临床研究于中国境内完成首例患者给药。公司计划在条件具备后进一步在美国等地开展该国际多中心临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607163809105454.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607163809105454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000306685.HKD","BMED","HK0000165453.HKD","BK1161","IBBQ","HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124290632","title":"复宏汉霖（02696）PD-1生物类似药HLX18全球多中心Ⅰ期试验在中国完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1124290632","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124290632?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:43","pubTimestamp":1784191382,"startTime":"0","endTime":"0","summary":"2026年7月16日，复宏汉霖发布自愿公告称，其自主研发的纳武利尤单抗生物类似药HLX18在多种已切除实体瘤患者中开展的国际多中心Ⅰ期临床研究，已于中国境内完成全球首例患者给药。公司计划在条件具备后，在美国等地继续推进该试验。2025年12月和2026年3月，HLX18分别在美国及中国境内获准开展针对多种实体瘤的Ⅰ期临床试验。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651417323","title":"复宏汉霖(02696.HK)：纳武利尤单抗生物类似药HLX18 (重组抗PD-1人源化单克隆抗体注射液)在多种已切除实体瘤患者中开展的国际多中心1期临床研究于中国境内完成全球首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2651417323","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651417323?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:32","pubTimestamp":1784190757,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000320223.HKD","HK0000306685.HKD","HK0000320264.USD","HK0000165453.HKD","02696","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651352154","title":"术后或可“去化疗” 复宏汉霖H药破解胃癌临床痛点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651352154","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651352154?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:53","pubTimestamp":1784083980,"startTime":"0","endTime":"0","summary":"7月11日，由中国健康促进与教育协会主办、北京抗癌协会提供学术支持的“第一届胃癌围术期免疫治疗创新大会”召开。记者从大会现场获悉，对于可切除胃癌，围术期是提升治愈率、实现长期生存的关键窗口期，也是实现胃癌诊疗关口前移的重要阵地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153807210878.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807210878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000320223.HKD","HK0000306701.USD","02696","HK0000320264.USD","BK1161","HK0000306685.HKD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651191714","title":"复宏汉霖H药全球布局加速兑现商业价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2651191714","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651191714?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:08","pubTimestamp":1783930080,"startTime":"0","endTime":"0","summary":"7月13日消息，在近日举行的“第一届胃癌围术期免疫治疗创新大会”期间，复宏汉霖执行董事、首席执行官朱俊在致辞中表示：“复宏汉霖长期深耕肿瘤等高发疾病领域，如今已将胃癌围术期免疫治疗方案切实带到患者身边。过去，胃癌患者承受着沉重的化疗负担；而今天，围术期患者已实现‘高质量去化疗’，迈向长生存的新阶段。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-07-13/doc-inihrxcc2264665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000306685.HKD","HK0000320223.HKD","02696","BK1161","HK0000306701.USD","HK0000320264.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198039749","title":"复宏汉霖HLX37联合疗法获批开展Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1198039749","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198039749?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:36","pubTimestamp":1783672588,"startTime":"0","endTime":"0","summary":"2026年7月10日，复宏汉霖生物技术股份有限公司发布自愿公告称，其自主研发的HLX37联合化疗或HLX43用于晚期/转移性实体瘤治疗的Ⅰ期临床试验申请已获国家药品监督管理局批准。公司计划在条件具备后于中国境内开展相关临床研究。公司称，截至公告披露日，全球尚无同类“HLX37联合化疗或HLX43”用药方案获批上市。复宏汉霖强调，HLX37及HLX43仍处于临床开发阶段，能否最终获批商业化尚存在不确定性。本次公告由复宏汉霖董事会主席张文杰签署并发布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183182","title":"复宏汉霖(02696.HK)：HLX37联合化疗或注射用HLX43用于晚期/转移性实体瘤治疗的 1期临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183182","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650183182?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:32","pubTimestamp":1783672375,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000165453.HKD","HK0000306701.USD","02696","HK0000306685.HKD","BK1161","HK0000320264.USD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649964779","title":"复宏汉霖(02696)：西妥昔单抗注射液生物类似药HLX05-N在转移性结直肠癌(mCRC)患者中的1期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2649964779","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649964779?lang=zh_cn&edition=full","pubTime":"2026-07-08 17:27","pubTimestamp":1783502848,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的西妥昔单抗注射液生物类似药HLX05-N在转移性结直肠癌患者中的1期临床研究于中国境内完成首例患者给药。本研究是一项在KRAS/NRAS野生型且BRAF V600E无突变的转移性结直肠癌参与者中，比较HLX05-N与美国及欧盟来源Erbitux联合化疗 治疗的多中心、随机、双盲、平行对照1期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320223.HKD","HK0000165453.HKD","LU2473716301.USD","HK0000306701.USD","PPH","02696","HK0000306685.HKD","LU2322448791.USD","HK0000320264.USD","XPH","IBB","IE00B5TLWC47.USD","LU2272731865.HKD","BK1161","LU1992135472.HKD","BK4588","BK4585","LU2322448957.HKD","LU1992135399.USD","LU2272731600.USD","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0598},{"period":"3month","weight":-0.003},{"period":"6month","weight":-0.0434},{"period":"1year","weight":-0.1513},{"period":"ytd","weight":0.1797}],"compareEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.0177},{"period":"3month","weight":-0.0326},{"period":"6month","weight":-0.0546},{"period":"1year","weight":-0.0158},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.12138},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.033714},{"month":6,"riseRate":0.571429,"avgChangeRate":0.085211},{"month":7,"riseRate":0.428571,"avgChangeRate":0.040127},{"month":8,"riseRate":0.571429,"avgChangeRate":0.009153},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}